Download MendeleyDiscovery and Evaluation of Clinical Candidate IDH305, a Brain Penetrant Mutant IDH1 Inhibitor.
Cho, Y.S., Levell, J.R., Liu, G., Caferro, T., Sutton, J., Shafer, C.M., Costales, A., Manning, J.R., Zhao, Q., Sendzik, M., Shultz, M., Chenail, G., Dooley, J., Villalba, B., Farsidjani, A., Chen, J., Kulathila, R., Xie, X., Dodd, S., Gould, T., Liang, G., Heimbach, T., Slocum, K., Firestone, B., Pu, M., Pagliarini, R., Growney, J.D.(2017) ACS Med Chem Lett 8: 1116-1121
- PubMed: 29057061
- DOI: https://doi.org/10.1021/acsmedchemlett.7b00342
- Primary Citation of Related Structures:
6B0Z - PubMed Abstract:
Inhibition of mutant IDH1 is being evaluated clinically as a promising treatment option for various cancers with hotspot mutation at Arg 132 . Having identified an allosteric, induced pocket of IDH1 R132H , we have explored 3-pyrimidin-4-yl-oxazolidin-2-ones as mutant IDH1 inhibitors for in vivo modulation of 2-HG production and potential brain penetration. We report here optimization efforts toward the identification of clinical candidate IDH305 ( 13 ), a potent and selective mutant IDH1 inhibitor that has demonstrated brain exposure in rodents. Preclinical characterization of this compound exhibited in vivo correlation of 2-HG reduction and efficacy in a patient-derived IDH1 mutant xenograft tumor model. IDH305 ( 13 ) has progressed into human clinical trials for the treatment of cancers with IDH1 mutation.
Organizational Affiliation:
Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States.
